Ensayos clínicos

Inclusion Criteria:

- Patients with unresectable or metastatic disease who are refractory to or are not
candidates for standard approved therapy

- Histologic confirmation of malignancy

- Measurable disease per RECIST v1.1

- Eastern Cooperative Oncology Group Performance Status (ECOG) of 0 or 1

- Participants must have adequate organ function as defined by lab tests

- Part 1: Following tumor types: Breast cancer, cervical cancer, colorectal cancer,
adenocarcinoma or squamous cell carcinoma of the esophagus, gastric or
gastroesophageal junction adenocarcinoma, squamous cell carcinoma of the head and
neck, hepatobiliary cancers (hepatocellular carcinoma (HCC), gallbladder cancer,
cholangiocarcinoma), non-small cell lung cancer, renal cell carcinoma, squamous cell
carcinoma of the skin, or urothelial carcinoma

- Part 2: Following tumor types: Squamous cell carcinoma of the head and neck, Gastric
or gastroesophageal junction adenocarcinoma, Non-small cell lung cancer

Exclusion Criteria:

- Active, known or suspected autoimmune disease

- Condition requiring systemic treatment with either corticosteroids or other
immunosuppressive medications

- Brain or leptomeningeal metastases

- Known history of positive test for HIV

- Non-HCC patients: acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV);
HCC patients: untreated active HBV or dual infection with HBV/HCV

- Participants after solid organ or allogeneic hematopoietic stem cell transplant

- History of life-threatening toxicity related to prior immune therapy

- History of life-threatening toxicity related to prior cetuximab or other anti-EGFR
antibodies (for Sub-Part 1C)

- Unstable or deteriorating cardiovascular disease within the previous 6 months

- Any major surgery within 4 weeks of study drug administration

- Prior/Concomitant Therapy:

- Cytotoxic/Non-cytotoxic anti-cancer agents, unless at least 4 weeks have elapsed from
last dose

- Use of other investigational drugs within 28 days

- Prior treatment with macrophage or natural killer (NK) cells activating therapies

- Administration of a live attenuated vaccine within 28 days

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 11/9/22. Questions regarding updates should be directed to the study team contact.